Table 4.
Treatment-emergent adverse events occurring in ≥15% of patients treated with isatuximab (Isa) carfilzomib (K) dexamethasone (d) (Isa-Kd), according to the renal impairment status – safety population.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.